Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review Article

Prevalence of anxiety during the COVID-19 pandemic: A systematic review and meta-analysis of over 2 million people

Felipe Mendes Delpino a,*, Carine Nascimento da Silva b, Jeferson Santos Jerônimo d, Eliete Stark Mulling d, Larissa Leal da Cunha d, Marina Krause Weymar d, Ricardo Alt c, Eduardo L. Caputo d, Natan Feter e

a Postgraduate Program in Nursing, Federal University of Pelotas, Rio Grande do Sul, Brazil
b Postgraduate Program in Health Sciences, Federal University of Rio Grande, Rio Grande do Sul, Brazil
c Postgraduate Program in Epidemiology, Federal University of Pelotas, Rio Grande do Sul, Brazil
d Postgraduate Program in Physical Education, Federal University of Pelotas, Rio Grande do Sul, Brazil
e Postgraduate Program in Epidemiology, Federal University of Rio Grande do Sul, Rio Grande do Sul, Brazil

ARTICLE INFO

Keywords:
Anxiety
COVID-19
Coronavirus
Pandemic

ABSTRACT

Introduction: Uncertainty, disruptions in daily routines, and concerns for the health and well-being during the COVID-19 pandemic are likely associated with increases in generalized anxiety. The present study aimed to systematically review the literature in order to identify the update prevalence of anxiety in the general population during the COVID-19 pandemic.

Methods: A systematic review and meta-analysis. It included studies that assessed the prevalence of anxiety among the general population during the COVID-19 pandemic.

Results: In total, we included 194 studies. The general prevalence of anxiety was 35.1 %, affecting approximately 851,000 participants. The prevalence in low and middle-income countries (35.1 %; 95%CI: 29.5 % to 41.0 %) was similar compared to high-income countries (34.7 %; 95%CI: 29.6 % to 40.1 %). In studies that provided the proportion of cases in each level of anxiety disorder, mild-to-moderate anxiety affected one quarter of the participants. One in ten cases with anxiety during the COVID-19 may be living with severe or extremely anxiety disorder. Most instruments estimated similar prevalence of anxiety disorders with notable difference in the prevalence estimated by the Generalized Anxiety Disorder 2-item (GAD-2), Zung Self-Rating Anxiety Scale (SAS), and State-Trait Anxiety Inventory (STAI).

Conclusion: One in three adults were living with anxiety disorder during the COVID-19 pandemic worldwide.

1. Introduction

Anxiety disorders are the most prevalent mental disorder and were a leading cause of health loss worldwide in 2019, reaching approximately 301 million (Yang et al., 2021). It is characterized by feelings of anxiety and fear, including phobias, generalized anxiety, panic, and social anxiety disorder (WHO, 2017). The duration of symptoms typically experienced by people with anxiety disorders characterized it as a chronic condition (Cheng et al., 2020). The long-term consequences of anxiety include chemical changes in the brain such as increased release of stress hormones, resulting in increased frequency or intensity of other conditions such as dizziness, headache, and depression (Racine et al., 2021).

The COVID-19 pandemic has tackled the global health as one of the greatest public health crises. Uncertainty, disruptions in daily routines, and concerns for the health and well-being of family and loved ones during the COVID-19 pandemic are likely associated with increases in generalized anxiety (Santomauro et al., 2021). Previous study estimated a significant correlation between human mobility and daily SARS-CoV-2 infection rate with the change in anxiety disorder prevalence (Matthew et al., 2021). Between 2010 and 2019, the number of people living with anxiety disorder increased by 11.2 %, summing roughly 30 million new cases worldwide (Yang et al., 2021). In the first year of the COVID-19 pandemic (March 2020 to January 2021), approximately 76 million new cases of anxiety disorder were identified, representing a 25 % upsurge in cases (Matthew et al., 2021). Therefore, this study aimed to
update the prevalence of anxiety in the general population during the COVID-19 pandemic up to January 2022.

2. Methods

2.1. Search strategy

We conducted a systematic review and meta-analysis that followed the new PRISMA statement (Matthew et al., 2021). The searches were concluded in June 2021 by two reviewers (FMD and CNS) and included the following databases: Pubmed, Lilacs, Web of Science, and PsyctiNFO. We utilized two groups of keywords, based on MeSH and non-MeSH terms, to perform the searches: Anxiety OR Angst OR Social Anxiety AND COVID-19 OR COVID 19 OR Pandemics. The present systematic review and meta-analysis were registered and approved by the PROSPERO under the protocol number: CRD42021261660.

2.2. Inclusion and exclusion criteria

We included studies that met the following criteria: 1- investigated the prevalence of anxiety in the general population during the COVID-19 pandemic; 2- Observational studies (cross-sectional and/or longitudinal); 3- Samples with adults aged 18 or above.

The criteria for exclusion were: 1- Duplicated studies or those with the same database; 2- Studies conducted with individuals with specific characteristics (e.g., nurses, healthcare workers, cancer patients, COVID-19 patients, pregnant women, students); 3- Articles that full-text was not available; 4- Articles that lacked data to include in the meta-analysis.

2.3. Study selection

Studies selection (i.e. title, abstract and full-text screening) was performed independently by two reviewers (FMD and CNS); any disagreements between reviewers were solved by consensus.

2.4. Meta-analysis

We performed a meta-analysis to assess the prevalence of anxiety during the COVID-19 pandemic. The results were presented as relative frequencies (%) with their respective 95% confidence intervals (95% CI). The I² test was used to assess heterogeneity between studies, considering values above 50 % and p-value <0.05 as high heterogeneity.

If more than one study used the same database, only one was included in the review to avoid overlapping participants. For studies that reported prevalence in %, we estimated the total number of individuals with anxiety.

We performed sub-group analyzes according to country income (low and middle income vs. high-income country vs mixed, studies that included countries of different income level), anxiety measurement instrument, and level of anxiety (mild, moderate, severe, and extremely severe). Analyzes were performed using the Meta package (Schwarzer, 2016), through the R programming language.

2.5. Quality of evidence

The Newcastle-Ottawa Scale (NOS) was used to assess the quality of evidence (Wells et al., 2000). This scale consists of eight items related to study selection, comparability, and outcome. For cohort studies, the original version of the NOS scale was used; for cross-sectional studies we used an adapted version from the original scale, based on a previous publication (Herzog et al., 2013). In NOS, the study received a star if classified as high quality in each item, except for the comparability item, which it can score two stars. Thus, the total NOS score varies from 0 to 9 for cohort studies and from 0 to 8 for cross-sectional studies. We also performed a funnel plot and Egger's test to determine the publication bias across the studies.

3. Results

3.1. Study description

We found 3740 original papers and 3570 after excluding duplicates (see Fig. 1). After titles, abstract and full-text screening, 194 were included in this review (Alamri et al., 2020; Alhalafi, 2020; Alkhameeet al., 2020; Aisalman et al., 2020; Barros et al., 2020; Basar et al., 2020; Bauerle et al., 2020; Benke et al., 2020; Bigalke et al., 2020; Casagrande et al., 2020; Castelli et al., 2020; Chauhan et al., 2020; Choi et al., 2020; Cortés-Alvarez et al., 2020; Dababseh et al., 2020; Daly and Robinson, 2020; Every-Palmer et al., 2020; Ey et al., 2020; Fiorillo et al., 2020; Galindo-Vázquez et al., 2020; Gallagher et al., 2020; Gao et al., 2020; García-Alvarez et al., 2020; González-Sanguino et al., 2020; Gorrochategui et al., 2020; Gualano et al., 2020; Guo et al., 2020; Hammarberg et al., 2020; Hossain et al., 2020; Hou et al., 2020; Huang and Zhao, 2020; J. Huang et al., 2020; Y. Huang et al., 2020; Hyland et al., 2020; Idrisii et al., 2020; Jiang et al., 2020; Li and Abir, 2020; Jia et al., 2020; Karatzias et al., 2020; Kujawa, 2020; Lei et al., 2020; Liu et al., 2020; Losada-Baltar et al., 2020; Lu et al., 2020; Madani et al., 2020; Mani et al., 2020; Massad et al., 2020; Mazza et al., 2020; McCracken et al., 2020; Mirhosseini et al., 2020; Moghanibashi-Mansourieh, 2020; Mohammadzadeh et al., 2020; Naga et al., 2020; Nwachukwu et al., 2020; Ocampo et al., 2020; Pérez-Cano et al., 2020; Petzold et al., 2020; Ping Wang et al., 2020; Plancho-O-Ruiz-Moreno et al., 2020; Qian et al., 2020; Ran et al., 2020; Ran et al., 2020; Riaza et al., 2020; Robb et al., 2020; Seyyed et al., 2020; Shangguan et al., 2020; Sherman et al., 2020; Shevlin et al., 2020; Shi et al., 2020; Silva et al., 2020; Sinawi et al., 2020; Solomon and Constantindou, 2020; Stanton et al., 2020; Steinmetz et al., 2020; Su et al., 2020; Szabó et al., 2020; Tee et al., 2020; Thomas et al., 2020; Tian et al., 2020; Traunmüller et al., 2020; Twenge and Joiner, 2020; Velikonja et al., 2020; Verma and Mishra, 2020; C. Wang et al., 2020; S. Wang et al., 2020; Wong et al., 2020; Zhang et al., 2020a; Zhang et al., 2020b; H. Zhao et al., 2020; Z. Zhao et al., 2020; Abdullah et al., 2021; Akaš et al., 2021; Al-Ajlouni et al., 2021; Aharon et al., 2021; Aljawad et al., 2021; Alqahtani et al., 2021; Alyami et al., 2021; Anidyanjati et al., 2021; Batterham et al., 2021; Bendau et al., 2021; Birhanu et al., 2021; Bibas et al., 2021; Boeteng et al., 2021; Bonati et al., 2021; Brown et al., 2021; Burkova et al., 2021; Cai et al., 2021; Canes et al., 2021; Cárdenas-García et al., 2021; Cénat et al., 2021; Chen et al., 2021; Chodkiewicz et al., 2021; Chopra et al., 2021; Cordaro et al., 2021; Das et al., 2021; Dubovi et al., 2021; El Desouky et al., 2021; El Keshty et al., 2021; Erasmus and Havnen, 2021; Fancourt et al., 2021; Feter et al., 2021; Fountoulakis et al., 2021; Freitas et al., 2021; Fu et al., 2021; Gogola et al., 2021; Gong et al., 2021; Goularte et al., 2021; Grover et al., 2021; Horigian et al., 2021; Hou et al., 2021; Hubbard et al., 2021; Huang et al., 2021; Hu and Umeda, 2021; Hyland et al., 2021; Jané-Llopis et al., 2021; Kar et al., 2021; Kaufman-Shriqui et al., 2021; Khademian et al., 2021; Khubchandi et al., 2021; Korkmaz and Güloğlu, 2021; Lemieux et al., 2021; C. H. Liu et al., 2021; Y. Liu et al., 2021; Mautong et al., 2021; M. Wang et al., 2021; Q. Wang et al., 2021; W. Wang et al., 2021; Y. Wang et al., 2021; Winkler et al., 2021;
Wolfson et al., 2021; Wong et al., 2021; Yan et al., 2021; Zarrouq et al., 2021; Zhong et al., 2021; J. Zhu et al., 2021; K. Zhu et al., 2021; Zou et al., 2021. Most studies (n = 110) were removed because they did not assess the prevalence of anxiety, followed by 29 studies that did not provide data for meta-analysis.

3.2. Studies characteristics

Of the 194 studies included, 106 were published in 2020 and 88 were published in 2021. Most studies (n = 176, 89.3 %) had a cross-sectional design and 21 (10.7 %) were longitudinal. The studies samples ranged from 71 (Freitas et al., 2021) to 790,633 (Vahratian et al., 2021) participants. The most used instrument to assess anxiety symptoms was the GAD-7 (General Anxiety Disorder-7) (n = 74), followed by DASS-21 (Depression, Anxiety and Stress Scale) (n = 42). Most studies were carried out with both sexes (n = 193), four were only with women and none with men only. The studies were conducted in the South and North America, Europe, Africa, Asia, and Oceania continents. Most of the studies were carried out in China (n = 37), followed by United Stated (n = 18) and Brazil (n = 11).

3.3. Meta-analysis

Fig. 2 shows the forest plot for the general prevalence of anxiety during COVID-19 and the stratified prevalence according to the anxiety scale. The general analysis included >2.4 million people, of which 35.12 % had anxiety. When stratified by measurement scale, the STAI scale presented the higher prevalence, 66.66 % (95%CI: 57.88–74.43), whereas the GAD-2 showed the lower prevalence, 19.93 % (95%CI: 13.24–28.87).

As illustrated in Fig. 3, the analysis stratified by country's income showed that the prevalence of anxiety in low- and middle-income countries was 35.06 % (95%CI: 29.54–41.00), while the prevalence in high-income countries was 34.66 % (95%CI: 29.59–40.10). In Fig. 4, the prevalence of mild anxiety disorder was 15.45 % (95%CI: 13.21–17.98), affecting approximately 513,000 participants, followed by moderate (12.63 %; 95%CI: 10.41–15.26), severe (6.74 %; 95%CI: 5.32–8.51), and extremely severe (5.65 %; (95%CI: 4.09–7.75).

3.4. Risk of bias

Regarding longitudinal studies, the NOS score ranged from two to eight points, with a media of six points. Concerning the cross-sectional studies, four of them scored only one point, while four scored eight points. The mean score of cross-sectional studies was five points. Our funnel plot (Fig. 5) presented an asymmetry to the left, and the results were confirmed by Egger’s test (p = 0.0001), which may be due to heterogeneity among the studies.
4. Discussion

In this study, we evaluated the prevalence of anxiety across the general population during the COVID-19 pandemic. We found that around 35% of the sample presented anxiety during the COVID-19 pandemic, which represents roughly 851,000 people with this condition worldwide. We also found that >500,000 participants suffered from mild anxiety levels (15.45%), and 112,000 (5.65%) suffered from extremely severe anxiety levels. No differences were observed in anxiety prevalence based on countries’ income. We showed that the studies utilizing the STAI scale presented a higher anxiety prevalence, whereas those with the GAD-2 showed a lower prevalence.

A recent meta-analysis with 48 studies estimated an additional 76.2 million cases of anxiety disorders, causing ≈44.5 million disability-adjusted life-years (Santomauro et al., 2021). Another previous meta-analysis found an anxiety prevalence of 21% for the general population (Dragioti et al., 2022), smaller results than our findings. The differences in the number of participants may explain the prevalence of anxiety. We included >2.4 million participants, whereas the previous meta-analysis evaluated anxiety, depression, stress, sleep problems, and posttraumatic symptoms, included ~500 thousand participants. Moreover, the number of subjects for anxiety was not specified. Another hypothesis for the differences is that the searches for the previous meta-analysis occurred until late September 2020, only six months since the beginning of the COVID-19. Meanwhile, our searches were conducted until the end of June 2021, when the pandemic had been going on for 1.3 years. Another meta-analysis with 43 studies published until August 2020, found an overall prevalence of anxiety of 25%, with significant differences concerning the anxiety measurement methods (Santabarbara et al., 2021). Recently, a meta-analysis with 103 studies published until February 2021, and ~140 thousand participants, found a prevalence of anxiety was 27.3% among the general population (Pashazadeh Kan
et al., 2021).

Overall, our findings suggested that one in three people worldwide suffered from anxiety disorder during the COVID-19 pandemic. By the time of this study, the curve of cases and deaths were attenuated or even declining in most countries. However, the long-term consequences of this rapidly increase in anxiety prevalence are still unknown. High prevalence of anxiety disorders and the associated excessive mortality have a huge impact on public health (Higgins and Thompson, 2002). For example, people with anxiety disorders are more likely to suffer from other chronic conditions such as depression. Also, people with an anxiety disorder are three to five times more likely to go to the doctor and six times more likely to be hospitalized for psychiatric disorders than individuals without anxiety. In addition, persistent symptoms of COVID-19 infection, also known as long COVID-19, may exacerbate the pandemic impact in mental health at populational level. A protocol study proposed to evaluate this interaction and future results may confirm this hypothesis (Merikanto et al., 2022). On the other hand, pharmacological and non-pharmacological treatments for anxiety disorders are widely recognized. Further, public policies and campaigns to improve awareness about anxiety disorder should be encouraged in order to reduce stigma and provide adequate access to diagnosis and treatment.

Furthermore, our study does not observe a significant association between the prevalence of anxiety disorder and countries' income, corroborating previous findings (Yang et al., 2021; WHO, 2017; Matthew et al., 2021). An investigation with data from the Global Burden of Disease Study showed the highest prevalence of anxiety disorder in countries with middle socio-demographic index (a composite indicator of income per capita, years of education, and fertility). However, no differences were observed in the prevalence of anxiety in any
anxiety symptoms and disorder: Hospital Anxiety and Depressive Scale examined the variations of three different instruments used to screen statistically different than the overall prevalence. A previous study confirmed by the I treatments such as the high heterogeneity among studies, which was expected to be very cost effective by offsetting the functional impairments associated with anxiety disorders (Wells et al., 2000).

Moreover, a similar prevalence of anxiety disorder was estimated by different instruments. Only GAD-2, SAS, and STAI revealed prevalence expected to be very cost effective by offsetting the functional impairments associated with anxiety disorders (Wells et al., 2000).

The overall burden of anxiety disorders is very staggering and continues to increase, and it presents a huge heterogeneity in different sexes, locations and age groups. Understanding the specific characteristics of anxiety disorders burden across the world and reducing risk factors such as bullying, establishing effective mental health knowledge dissemination, improving early diagnosis and performing diversified intervention strategies are of utmost importance to formulate more effective and targeted intervention and control of anxiety disorders.

5. Conclusion

In conclusion, 35.12% of the general population had anxiety during the COVID-19 pandemic. We also found significant differences regarding the anxiety scale of measurement, whereas no differences were observed concerning low and middle-income countries compared to high-income countries.

Funding

None.

CRediT authorship contribution statement

FMD and CNS were the reviewers of the article. JSJ, ESM, LLC, MKW, RA, ELC, and NF contributed to the writing and preparation of the manuscript. All authors reviewed and contributed fully to the preparation of the manuscript.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgments

This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES)—Finance Code 001. During the preparation of the manuscript, FMD received a doctoral scholarship from the National Council for Scientific and Technological Development (CNPq).

References

Abdulrah, M.F.I.B., Ahmad, Yusof H., Mohd, Shariff N., Hami, R., Nisman, N.F., Law, K. S., 2021. Depression and anxiety in the Malaysian urban population and their association with demographic characteristics, quality of life, and the emergence of the COVID-19 pandemic. Curr. Psychol. 40 (12), 6259–6270. https://doi.org/10.1007/s12144-021-01492-2.

Aharon, A.A., Dubovi, I., Ruban, A., 2021. Differences in mental health and health-related quality of life between the Israeli and Italian population during a COVID-19 quarantine. Qual. Life Res. 30 (6), 1675–1684. https://doi.org/10.1007/s11136-020-02746-5.

Akalu, T.Y., Gelaye, K.A., Bishaw, M.A., Tilahun, S.Y., Yeshaw, Y., Azale, T., Tsegaye, T., Asmelash, D., Akalu, Y., 2021. Depression, anxiety, and stress symptoms and its associated factors among residents of Gondar town during the early stage of COVID-19 pandemic. Risk Manag. Healthc. Policy 14, 1073. https://doi.org/10.2147/RMHP.S296796.

Al-Ajlouni, Y.A., Park, S.H., Alawa, J., Shamaileh, G., Bawab, A., El-Sadr, W.M., Duncan, D.T., 2020. Original research: anxiety and depressive symptoms are associated with poor sleep health during a period of COVID-19-induced nationwide lockdown: a cross-sectional analysis of adults in Jordan. BMJ Open 10 (12). https://doi.org/10.1136/BMJOPEN-2020-041995.

Alalami, H.S., Alqarni, A., Shehata, S.F., Bshabshe, A.A, Alshehri, N.N., Alasiri, A.M., Hussain, A.H., Alalmay, A.Y., Alshehri, E.A., Akqarni, Y., Saleh, N.F., 2020. Prevalence of depression, anxiety, and stress among the general population in Saudi Arabia during Covid-19 pandemic. Int. J. Environ. Res. Public Health 17 (24), 1–11. https://doi.org/10.3390/ijerph171249183.

Alswaiz, H., Yokout, S.M., Wani, K., Alhumah, G.A., Ansari, M.G.A., Bhattacharjee, M.N.K., Hussain, S.D., Al-Daghashi, N.M., 2021. Dietary intake and mental health among Saudi adults during COVID-19 lockdown. BMC Psychiatry 18 (4), 1653. https://doi.org/10.3390/BMCPSYCHIATRY18041653.

Alghabani, A.S., Alrasheed, M.M., Almuanbi, A.M., 2021. Public response, anxiety and behaviour during the first wave of covid-19 pandemic in Saudi Arabia. Int. J. Environ. Res. Public Health 18 (9). https://doi.org/10.3390/IJERPH18094628.

Alhalafi, A.H., 2020. Prevalence of anxiety and depression during the coronavirus disease 2019 pandemic in Riyadh, Saudi Arabia: a web-based cross-sectional survey.
dwellers: an online cross-sectional survey. Am. Acad. Med. Singap. 49 (10),

Moayed, M.S., Vedahard-Azimi, A., Mirmomeni, G., Rahimi-Bashar, F., Goharimoghaddam, K., Pourshoheingoli, M.A., Abbasi-Farizadeh, M., Babaei, M., Sathyapalan, T., Guent, P.C., Sabehkar, A. 2021. A survey of psychological distress among the community in the COVID-19 epidemic: a cross-sectional study. Adv. Exp. Med. Biol. 1242, 55-63. https://doi.org/10.1007/978-3-030-73575-2_5.2.

Mohagheghi-Mansourieh, A., 2020. Assessing the anxiety level of iranian general population during COVID-19 outbreak. Asian J. Psychi. 51, 102076 https://doi.org/10.1016/j.ajp.2020.102076.

Mohammadzadeh, F., Delshad Nobahar, A., Khorasan, S., Bazieli, J., Armamehr, V., Paykani, T., 2020. Anxiety severity levels and coping strategies during the COVID-19 pandemic among people aged 15 years and above in Gohandal. Iran Arch. Med. Psychi. 2233-638. https://doi.org/10.29252/ijpm.105.0302.

Mongkhon, P., Ruengorn, C., Awiphan, R., Thavorn, K., Wongpakaran, N., Wongpakaran, T., Nychay, S., 2021. Exposure to COVID-19-related information and its association with mental health problems in Thailand: Nationwide, cross-sectional survey study. J. Med. Inter. Res. 23 (2), e25363 https://doi.org/10.1177/20551166211052170.

Montemiro-Castro, A., Monterroso-Blanco, A., González-Sequera, A., 2021. Perceived loneliness and severe sleep disorders in adult women during the Covid-19 quarantine: a cross-sectional study in Colombia. J. Prim. Care Community Health 12. https://doi.org/10.1177/2150579X211025170.

Moreira-Cirujanos (English Edition) 88 (5), 562. https://doi.org/10.24875/cirujanos.202000361.

Morales-Murguía, M.B., García-Morales, M., España, M., Surood, S., Urichuk, L., Cao, B., Greenshaw, A.J., Agyapong, V.I.O., 2020. COVID-19 pandemic: demographic predictors of self-isolation or self-quarantine and impact of isolation and quarantine on stress, anxiety, and depression. Front. Psychiatry 12, 553468. https://doi.org/10.3389/fpsyt.2020.553468.

Moughabachi, M., Sahebkar, A., Goharimoghaddam, K., Pourshoheingoli, M.A., Abbasi-Farizadeh, M., Babaei, M., Sathyapalan, T., Guent, P.C., Sabehkar, A. 2021. A survey of psychological distress among the community in the COVID-19 epidemic: a cross-sectional study. Adv. Exp. Med. Biol. 1242, 55-63. https://doi.org/10.1007/978-3-030-73575-2_5.2.

Munthe-Kaas, J., Kolboe, H., Helge, J.O., Jacobsen, T., Torp-Pedersen, C., Baksaas, E., Krokstad, S., 2021. Incidence and development of anxiety disorders and depression in the population during the COVID-19 pandemic: a population-based study. Psychol. Med. 51 (2), 273-284. https://doi.org/10.1017/S0033291720001803.
Santab Rondung, E., Leiler, A., Meurling, J., Björn, M., Abid, M., Bano, Z., 2020. Psychological Problems in General Ren, Z., Zhou, Y., Liu, Y., 2020. The psychological burden experienced by Chinese residents of an urban slum in North India. J. Neurosci. Rural Pract. 12 (1), 153–158. https://doi.org/10.3389/fpubh.2021.562437.

Sun, Y.K., Shi, J., Bao, Y.P., Lu, L., 2020. Prevalence and correlates of anxiety during the COVID-19 pandemic among adults in China. J. Affect. Disord. 277, 436–442. https://doi.org/10.1016/j.jad.2020.09.018.

Shi, Z., Qin, Y., Chair, S.Y., Liu, Y., Tian, Y., Li, X., Hu, W., Wang, Q., 2020. Anxiety and depression levels of the general population during the rapid spreading stage in the coronavirus disease 2019 outbreak: a cross-sectional online investigation in China. BMJ Open 11 (5), e050084. https://doi.org/10.1136/bmjopen-2021-050084.

Silva, L.B.B., Seguro, C.S., de Oliveira, C.G.M., de Oliveira, J.C.M., de Souza Filho, L.F.M., de Paula Júnior, C.A., Gentil, P., Rebelo, A.C.S., 2020. Physical inactivity is associated with increased levels of anxiety, depression, and stress in Brazilians during the COVID-19 pandemic: a cross-sectional study. Front. Psychiatry 11, 565291. https://doi.org/10.3389/fpsyt.2020.565291.

Somma, A., Kruger, R.F., Marken, K.E., Gauld, G., Colaino, M., Ferlito, D., Liotta, C., Frau, C., Fossati, A., 2021. A longitudinal study on clinically relevant self-reported depression, anxiety and acute stress features among Italian community-dwelling adults during the COVID-19 related lockdown: evidence of a predictive role for baseline dysfunctional personality dimensions. J. Affect. Disord. 282, 364–371.

F. M. Delpino et al.
Wang, M., Zhao, Q., Hu, C., Wang, Y., Cao, J., Huang, S., Li, J., Huang, Y., Liang, Q., Verma, S., Mishra, A., 2020. Depression, anxiety, and stress and socio-demographic

Velikonja, N.K., Erjavec, K., Verdenik, I., Hussein, M., Velikonja, V.G., 2020. Association

Vahratian, A., Blumberg, S.J., Terlizzi, E.P., Schiller, J.S., 2021. Symptoms of anxiety or depressive symptoms in 2019 and during the 2020 COVID-19 pandemic. Depress.

Traunmüller, C., Stefitz, R., Gaisbachgrabner, K., Schwerdtfeger, A., 2020. Psychological

Su, J., Chen, X., Yang, N., Sun, M., Zhou, L., 2020. Proximity to people with COVID-19

Wang, Y., Di, Y., Ye, J., Wei, W., 2021. Study on the public psychological states and its related factors during the outbreak of coronavirus disease 2019 (COVID-19) in some regions of China. Psychol Health Med. 26 (1), 13–22. https://doi.org/10.1080/13548506.2019.1746817.

Wolfe, L., Skea, O., O’Connell, D., Peterson, J. 2000. The Newark-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Ottawa, ON: Ottawa Hospital Research Institute [cited 2019 Nov 9]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

Winkler, P., Mohrva, Z., Milda, K., Kokleva, M., Kastgrom, A., Mohrb, P., Formanek, T., 2021. Prevalence of current mental disorders before and during the second wave of COVID-19 pandemic: an analysis of repeated nationwide cross-sectional surveys. J. Psychiatr. Res. 139, 167–171. https://doi.org/10.1016/j.jpsychires.2021.05.032.

Wolfson, J.A., García, T., Leung, C.W., 2021. Food insecurity is associated with depression, anxiety, and stress: evidence from the early days of the COVID-19 pandemic in the United States. Health Equity 5 (1), 64–71. https://doi.org/10.1007/s41701-020-0229-x.

Wong, L.P., Alias, H., Danan, M., Zaire, M., Aebi, F., Atia, M., Mohajer, S., HajAliIlbegri, R., Nia, M.N., Jamei, F., Mazlom, S.R., 2020. Uncovering psychosocial implications of SARS-CoV-2 infection in Iran. Transbound Emerg Dis. 67 (6), 2892–2900. https://doi.org/10.1111/TBED.13662.

Wong, L.P., Alias, H., Fuzi, A., Omar, I.S., Mohammad Nor, A., Tan, M.P., Baranovich, D. L., Saari, C.Z., Hannnah, S.H., Cheong, K.W., Poon, C.H., Ramoo, V., Che, C.C., Myint, K., Zainuddin, S., Chung, I., 2021. Escalating progression of mental health disorders during the COVID-19 pandemic: evidence from a nationwide survey. PLoS ONE 16 (3), e0248916. https://doi.org/10.1371/journal.pone.0248916.

World Health Organization, 2017. Depression and other common mental disorders: global health estimates [Internet] [cited 2022 Apr 3]. Available from: https://apps.who.int/iris/handle/10665/254610.

Yang, X., Fang, Y., Chen, Z., Zhu, T., Yin, X., Man, J., Yang, L., Lu, M., 2021. Global, regional and national burden of anxiety disorders from 1990 to 2019: results from the global burden of disease study 2019. Epidemiol. Psychiatr. Sci. 30, e6 https://doi.org/10.1136/epidemiologia-2020-131075.

Yan, T., Zhihong, W., Jianhong, Z., Yubo, Y., Jie, L., Junjun, Z., Guanzh, L., 2021. Depressive and anxiety symptoms among people under quarantine during the COVID-19 epidemic in China: a cross-sectional study. Front. Psychiatry. 12, 566241. https://doi.org/10.3389/FPSYT.2021.566241.

Zarrouq, B., Abbas, N., Hilaey, J.E., Azi, A.E., Abbouyi, S., Oumari, M., Maliki, H., Bouanza, S., Moutawakkil, S.G., Halim, K., Ragala, M.E., 2021. An investigation of the association between religious coping, fatigue, anxiety and depressive symptoms during the COVID-19 pandemic in Morocco: a web-based cross-sectional survey. BMC Psychiatry 21 (1), 264. https://doi.org/10.1186/s12888-021-02371-6.

Zhang, Y., Chen, Y., Zang, X., Chen, J., Zhao, J., He, X., 2021. COVID-19 related symptoms of anxiety, depression, and PTSD among US adults. Psychiatry Res. 301, 113959 https://doi.org/10.1016/j.psychres.2020.112992.

Zou, C., Zhang, W., Sznajder, K., Yang, F., Jia, Y., Ma, R., Cui, C., Yang, X., 2021. Factors associated with COVID-19 infection outbreak increases anxiety level of general public in China: involved mechanisms and influencing factors. J. Affect. Disord. 276, 446–452. https://doi.org/10.1016/j.jad.2020.07.085.

Zhao, S.Z., Wong, J.T.H., Lat, T.W.T., Lam, A.C.K., Lam, T.H., Wang, M.P., 2020. Mental health crisis under COVID-19 pandemic in Hong Kong: a cross-sectional study. J. Psychosom. Res. 138. https://doi.org/10.1016/j.j psychosom. res.2020.0059/SUPPL_FILE/SUPP_FIGS2.DOCX.

Zhou, H., Xie, X., Fan, G., Li, L., Huang, Q., Qiu, K., Kang, Z., Du, T., Han, L., Ding, L., Xu, H., 2020. COVID-19 infection outbreak increases anxiety level of general public in China: involved mechanisms and influencing factors. J. Affect. Disord. 276, 446–452. https://doi.org/10.1016/j.jad.2020.07.085.

Zhong, J., Zang, C., Qiu, L., Li, J., Lai, L., Lu, W., Wang, Z., Zhong, J., Zhao, J., Zou, Y., 2021. Risk and protective factors for anxiety during COVID-19 pandemic. BMC Public Health 21 (1), 1260. https://doi.org/10.1186/s12889-021-03798-0.

Zhu, K., Niu, Z., Freudenheim, J.L., Zhang, Z.F., Lei, L., Homish, G.G., Cao, Y., Zorich, S. C., Yue, Y., Liu, R., Mu, L., 2021. COVID-19 related symptoms of anxiety, depression, and PTSD among US adults. Psychiatry Res. 301, 113959 https://doi.org/10.1016/j.psychres.2020.112992.

Zou, C., Zhang, W., Szajdjer, K., Yang, F., Jia, Y., Ma, R., Cui, C., Yang, X., 2021. Factors influencing anxiety among WeChat users during the early stages of the COVID-19 pandemic in mainland China: cross-sectional survey study. J. Med. Internet Res. 23 (5), e24412 https://doi.org/10.2196/24412.